IMMU-11. NONO IS A NEW ADENOVIRUS SENSOR: IMPLICATION FOR VIROTHERAPY

The median survival for GBM patients is 15 months with a five-year survival rate of less than 10%. Current conventional and experimental treatments, including immune checkpoint blockade, have not improved outcomes in the vast majority of glioma patients. Oncolytic viruses (OVs) are designed to speci...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2022-11, Vol.24 (Supplement_7), p.vii133-vii133
Hauptverfasser:	Gillard, Andrew, Shin, Dong Ho, Laspidea, Virginia, Singh, Sanjay K, Jiang, Hong, Kim, Debora, Fan, Xuejun, Yi, Yanhua, Lang, Frederick, Alonso, Marta M, Fueyo, Juan, Gomez-Manzano, Candelaria
Format:	Artikel
Sprache:	eng
Schlagworte:	Immunobiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!